Hovione has purchased 75% of Hisyn Pharmaceutical Co. Limited, based in Zhejiang. Hovione said the acquisition provides it with significant additional drug substance manufacturing production capacity and strengthens its 20 year presence in China. The acquisition includes development labs and a 22,000m2 API) plant, which will now produce Hovione's two largest volume products.
PR Newswire
Thursday 6 March 2008
Hovione invests in China
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment